Pengobatan Medis
Studi menemukan lecanemab membersihkan amiloid tetapi tidak menunjukkan pemulihan jangka pendek pada sistem pembersihan limbah otak
Dilaporkan oleh AI Gambar dihasilkan oleh AI Fakta terverifikasi
Peneliti di Universitas Metropolitan Osaka melaporkan bahwa meskipun obat Alzheimer lecanemab mengurangi plak amiloid, pengukuran MRI tidak menemukan perbaikan pada sistem pembersihan limbah glymphatic otak tiga bulan setelah pengobatan dimulai, yang menekankan kompleksitas penyakit dan kebutuhan pendekatan multi-target.
Servier Egypt has launched Tibsovo (ivosidenib), the first targeted therapy available in the country for patients with IDH1-mutated Acute Myeloid Leukemia (AML) and intrahepatic cholangiocarcinoma. The treatment offers a median overall survival of 29.3 months for eligible AML patients and 10.3 months for those with intrahepatic cholangiocarcinoma, according to clinical data. It is approved as a first-line treatment for AML and a second-line option for intrahepatic cholangiocarcinoma.
Dilaporkan oleh AI
Judy Wanyoike was diagnosed with stage 2B cervical cancer in 2012 following a Pap Smear test. Despite surgery, chemotherapy, and radiation therapy, the cancer returned in 2019 and again in 2022. Experts stress the need for early detection to prevent recurrence.